Elzonris

News

AbbVie's Decnupaz approval will give patients with rare blood cancer BPDCN an alternative to Stemline's Elzonris with a simpler dosing regimen.

Oncology

Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.